

# Natraj Proteins Limited

SOLVENT EXTRACTION PLANT & REFINERY  
Nagpur Kalan, Ordinance Factory Road, ITARSI

Ph.No. 07572- 262637, 262640, Fax No. 07572-262639

Email : natrajproteinltd@rediffmail.com

CIN : L00153 MP 1990 PLC 006090



Ref. : NPL/SE/2023

online filing at [www.listing.bseindia.com](http://www.listing.bseindia.com)

Date : 30<sup>th</sup> Nov., 2023

To,  
The General Manager  
DCS-CRD  
BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort  
MUMBAI - 400001

**BSE CODE: 530119**

**Subject: Submission of Reply to the E-mail dated 29<sup>th</sup> November, 2023 regarding discrepancies observed by the BSE for Corporate Announcement filed u/r 30 of SEBI (LODR) Regulations, 2015 for Submission of the Un-Audited Financial Results along with the Statement of Assets and Liabilities & Cash Flow Statement for the Quarter/Half year ended 30<sup>th</sup> September, 2023 And Limited Review Report u/r 33 of the SEBI (LODR) Regulations, 2015.**

Dear Sir/Ma'am,

This is with reference to the above captioned subject, regarding Additional details required by the email dated 29<sup>th</sup> November, 2023 at 3:13 P.M. as required under SEBI Circular dated September 09, 2015, for Corporate Announcement filed under Regulation 30 of SEBI (LODR) Regulations, 2015 with respect to the Submission of the Un-Audited Financial Results along with the Statement of Assets and Liabilities & Cash Flow Statement for the Quarter/Half year ended 30<sup>th</sup> September, 2023 and Limited Review Report u/r 33 of the SEBI (LODR) Regulations, 2015 observed by the BSE that *"Board Meeting Commencement and Concluded Time not Provided"*.

It may please be considered that the said Board Meeting was commenced at 3:00 P.M. concluded at 4:35 P.M. on 3<sup>rd</sup> November 2023 and the time of meeting commencement and conclusion was also disclosed while filing of results in the XBRL at the portal of BSE. This may be considered as compliance as required under Regulation 30 of the SEBI (LODR) Regulation as required under in the Para No. 4 of the Annexure of the Circular No. CIR/CFD/CMD/4/2015 dated 09.09.2015.

As per the aforesaid email we are pleased to submit a fresh corporate announcement for the aforesaid purposes.

I humbly request you to take the above clarification and take on record the aforesaid fresh corporate announcement on record.

Thanking You,  
Yours Faithfully,  
For, NATRAJ PROTEINS LIMITED

POOJA AGRAWAL  
COMPANY SECRETARY &  
COMPLIANCE OFFICER

Encl: Fresh Corporate Announcement Letter



# Natraj Proteins Limited

SOLVENT EXTRACTION PLANT & REFINERY  
Nagpur Kalan, Ordinance Factory Road, ITARSI

Ph.No. 07572- 262637, 262640, Fax No. 07572-262639

Email : natrajproteinltd@rediffmail.com

CIN : L00153 MP 1990 PLC 006090



Ref. :

NPL/SE/2023

Online filing at: [www.listing.bseindia.com](http://www.listing.bseindia.com)

Date :  
30<sup>th</sup> November, 2023

To,  
The General Manager  
DCS-CRD  
BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort  
MUMBAI - 400001

**BSE CODE: 530119**

**Sub: Submission of the Un-Audited Financial Results along with the Statement of Assets & Liabilities and Cash Flow Statement for the Quarter/ Half year ended 30<sup>th</sup> September, 2023 and Limited Review Report u/r 33 of the SEBI (LODR) Regulations, 2015.**

Dear Sir,

This is in continuation of our letter no. NPL/SE/2023 dated 25<sup>th</sup> October, 2023 and 26<sup>th</sup> October, 2023 regarding intimation of Board meeting for consideration and approval of the Un-Audited Financial Results along with the Statement of Assets & Liabilities and Cash Flow for the Quarter/Half year ended 30<sup>th</sup> September, 2023 and Limited Review Report thereon.

Pursuant to Regulation 33 of SEBI (LODR) Regulation, 2015 we are pleased to submit the following;

- Un-Audited Financial Results of the Company for the Quarter/ Half year ended 30<sup>th</sup> September, 2023;
- Limited Review Report by the Auditors for the Unaudited Financial Results of the Company for the Quarter/ Half year ended 30<sup>th</sup> September, 2023;
- Un-Audited Statement of Assets and Liabilities for the Half year ended 30<sup>th</sup> September, 2023;
- Un-Audited Statement of Cash Flow for the Half year ended 30<sup>th</sup> September, 2023.

which was considered and approved by the Board at their 5/2023-24 Meeting held on Friday, the 3<sup>rd</sup> November, 2023 at 3:00 P.M. and Concluded at 4.35 P.M.

The Financial Results will also be published in widely circulated English and Hindi (Vernacular) newspaper in the prescribed format for that purpose.

We are also in the process of filing the aforesaid financial results in the XBRL format within the stipulated time and same shall be hosted on the Website of the Company.

You are requested to please take on record the above said documents for your reference and record.

Thanking You,  
Yours Faithfully,

For, NATRAJ PROTEINS LIMITED

POOJA AGRAWAL  
COMPANY SECRETARY &  
COMPLIANCE OFFICER

Enclosed: a/a



# NATRAJ PROTEINS LIMITED

CIN: L00153MP1990PLC006090

Regd. Off. -Nagpur Kalan, Ordinance Factory Road, Itarsi, (M.P.)-461111

Ph No. 07572-262637, 262640, Fax No. 07572-262639

Email: natrajproteinltd@rediffmail.com

## Statement of Standalone Un-Audited Financial Results for the quarter and Half-Year ended on 30<sup>th</sup> Sept., 2023

Part I		(Rs. In Lakhs except EPS)					
Statement of Standalone Unaudited Financial Results for the Quarter/half year Ended 30 <sup>th</sup> September, 2023							
S. No.	Particulars	Quarter			Half Year		Year
		3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	6 months ended	Corresponding 6 months ended in the previous year	Previous year ended
		30/09/2023	30/06/2023	30/09/2022	30/09/2023	30/09/2022	31/03/2023
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Income/Revenue from Operations	3624.65	4058.54	3030.51	7683.19	5263.66	14359.72
II	Other Income	5.42	2.75	2.41	8.17	4.34	9.56
<b>III</b>	<b>Total Income (I+II)</b>	<b>3630.07</b>	<b>4061.29</b>	<b>3032.92</b>	<b>7691.36</b>	<b>5268.00</b>	<b>14369.28</b>
<b>IV</b>	<b>Expenses</b>						
A	Cost of Materials consumed	2869.20	2371.85	892.65	5241.05	1773.13	12082.34
B	Purchase of Stock-in-Trade	247.44	624.07	446.60	871.51	1962.76	2357.54
C	Changes in inventories of finished goods stock-in-trade and work-in-progress	835.17	1451.15	1644.02	2286.32	1302.29	(1099.02)
D	Employee benefits expense	35.74	26.10	24.12	61.84	55.87	118.39
E	Finance Costs	79.48	67.70	22.79	147.18	73.26	175.97
F	Depreciation and amortization expense	10.45	10.44	10.44	20.89	20.76	42.71
G	Other expenses	112.39	124.89	48.48	237.28	121.72	590.06
	<b>Total Expenses (IV)</b>	<b>4189.87</b>	<b>4676.20</b>	<b>3089.10</b>	<b>8866.07</b>	<b>5309.79</b>	<b>14267.99</b>
<b>V</b>	<b>Profit/ (Loss) before exceptional items and Tax (III -IV)</b>	<b>(559.8)</b>	<b>(614.91)</b>	<b>(56.18)</b>	<b>(1174.71)</b>	<b>(41.79)</b>	<b>101.29</b>
VI	Exceptional Items	-	-	-	-	-	-
<b>VII</b>	<b>Profit / (Loss) before tax (V -VI)</b>	<b>(559.8)</b>	<b>(614.91)</b>	<b>(56.18)</b>	<b>(1174.71)</b>	<b>(41.79)</b>	<b>101.29</b>
VIII	Tax expense:						
	(1) Current Tax	-	-	(1.32)	-	-	17.05
	(2) Deferred Tax	0.61	0.62	2.76	1.23	6.30	(13.46)
	(3) Income tax related to earlier years	-	-	-	-	-	-
<b>IX</b>	<b>Profit / (Loss) for the period from continuing operations (VII-VIII)</b>	<b>(560.41)</b>	<b>(615.53)</b>	<b>(57.62)</b>	<b>(1175.94)</b>	<b>(48.09)</b>	<b>70.78</b>
X	Profit / (Loss) from Discontinuing operations	-	-	-	-	-	-
XI	Tax expenses of Discontinuing operations	-	-	-	-	-	-
XII	Profit / (Loss) from Discontinuing operations	-	-	-	-	-	-



	(after Tax) (X-XI)						
<b>XIII</b>	<b>Profit / (Loss) for the period (IX+XII)</b>	<b>(560.41)</b>	<b>(615.53)</b>	<b>(57.62)</b>	<b>(1175.94)</b>	<b>(48.09)</b>	<b>70.78</b>
XIV	Other Comprehensive Income:						
	A (i) Items that will not be reclassified to Profit or loss	0.93	1.93	(0.95)	2.86	1.88	8.59
	(ii) Income Tax relating to items that will not be reclassified to Profit or loss		-	-		-	(2.23)
	B (i) Items that will be reclassified to profit or loss		-	-		-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or loss		-	-		-	-
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit/(Loss) and other Comprehensive Income for the period)	(559.48)	(613.60)	(58.57)	(1173.08)	(46.21)	77.14
XVI	Paid up Share Capital of the Company (Face Value Rs. 10/-)	374.70	374.70	374.70	374.70	374.70	374.70
XVII	Reserves excluding revaluation reserves	-	-	-	-	-	4248.38
XVIII	Earnings Per Share (for continuing operations)						
	(a) Basic	(14.95)	(16.43)	(1.53)	(31.38)	(1.28)	1.89
	(b) Diluted	(14.95)	(16.43)	(1.53)	(31.38)	(1.28)	1.89
XIX	Earnings Per Share (for Discontinued operations)						
	(a) Basic	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-
XX	Earnings Per Share (for Discontinued and continuing operations)						
	(a) Basic	(14.95)	(16.43)	(1.53)	(31.38)	(1.28)	1.89
	(b) Diluted	(14.95)	(16.43)	(1.53)	(31.38)	(1.28)	1.89

**Note :-**

1. The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 3<sup>rd</sup> November, 2023.
2. The above financial results are prepared in compliance with Indian Accounting Standards ("IND-AS") as notified under Section 133 of the Companies Act, 2013 ("the Act") [Companies (Indian Accounting Standards) Rules, 2015] as amended.
3. The company operates in two segments i.e., solvent extraction and commodities derivative trading. There was no requirement of segmental reporting as the sales of the commodities /derivatives are less than the threshold limits.
4. The Standalone Statement of Assets and Liabilities as at 30<sup>th</sup> September, 2023 and the Statement of Cash Flow is provided as an annexure to this statement.
5. As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter/half year ended on 30<sup>th</sup> September, 2023. The report does not have any impact on the above results and notes which needs explanation.



6. Previous period figures have been regrouped/ reclassified wherever necessary to confirm to this period classification.
7. Effective from 1<sup>st</sup> April, 2019, the company has adopted Indian Accounting Standard (IND-AS 116) "Leases" using the "Modified Prospective Approach". The adoption of the said IND AS did not have any impact on the retained earnings as at 1<sup>st</sup> April, 2023 and there was no material impact on financial results for the quarter ended on 30<sup>th</sup> September, 2023.

For, NATRAJ PROTEINS LIMITED




Date: 03.11.2023  
Place: Itarsi

**KAILASH CHAND SHARMA**  
Chairman & Managing Director  
DIN: 00012900

**STATEMENT OF AUDITED STANDALONE ASSETS AND LIABILITIES AS ON 30.09.2023**

Statement of Assets and Liabilities		( Rupees in Lakhs)	
Particulars	Note No.	Figures as at the end of current reporting period 30.09.2023	Figures as at the end of previous reporting period 31.03.2023
		Un-Audited	Audited
<b>ASSETS</b>			
<b>(1) Non-Current Assets</b>			
(a) Property, Plant and Equipment		373.99	394.64
(b) Capital Work-in-Progress		193.18	188.78
(c) Investment Property		-	-
(d) Goodwill		-	-
(e) Other Intangible assets		-	-
(f) Intangible assets under development		-	-
(g) Biological Assets other than bearer plants		-	-
(h) Financial Assets			
i. Investments		-	-
ii. Trade receivables		348.03	335.23
iii. Loans		228.41	228.97
iv. Others (to be specified)		-	-
(i) Deferred tax assets (net)		-	-
(j) Other non-current assets		229.72	288.52
<b>Total Non-Current Assets</b>		<b>1373.33</b>	<b>1436.14</b>
<b>(2) Current Assets</b>			
(a) Inventories		2703.60	5608.99
(b) Financial Assets			
i. Investments		44.41	43.32
ii. Trade receivables		835.51	1230.15
iii. Cash and cash equivalents		526.72	239.58
iv. Bank balances other than (iii) above		-	-
v. Loans		158.77	326.81
vi. Other (to be specified)		9.60	25.71
(c) Current Tax Assets (Net)		-	0.22
(d) Other current assets		-	-
<b>Total Current Assets</b>		<b>4278.61</b>	<b>7474.78</b>
<b>Total Assets</b>		<b>5651.94</b>	<b>8910.92</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
(a) Equity Share Capital		374.70	374.70
(b) Other Equity		3075.31	4248.38
<b>LIABILITIES</b>			
<b>(1) Non-current liabilities</b>			
(a) Financial Liabilities			
(i) Borrowings		259.44	250.60
(ii) Trade payables			
- Total outstanding dues of Micro and small enterprises;		-	-
- Total outstanding dues of creditors other than Micro and small enterprises;		-	-
(iii) Other Financial liabilities (other than those specified in item (b), to be specified)		-	-
(b) Provisions		-	-
(c) Deferred tax liabilities (Net)		-	-
(d) Other non-current liabilities		89.70	88.47
<b>Total Non-Current Liabilities</b>		<b>-</b>	<b>-</b>
<b>(2) Current liabilities</b>			
(a) Financial Liabilities		349.14	339.07



(i) Borrowings		1453.79	3118.78
(ii) Trade payables			
- Total outstanding dues of Micro and small enterprises;		54.38	9.50
- Total outstanding dues of creditors other than Micro and small enterprises;		119.24	643.45
(iii) Other Financial liabilities (other than those specified in item (c))		-	-
(b) Other current liabilities		171.13	177.04
(c) Provisions		54.25	-
(d) Current Tax Liabilities (Net)		-	-
<b>Total Current Liabilities</b>		<b>1852.79</b>	<b>3948.77</b>
<b>Total Equity and Liabilities</b>		<b>5681.94</b>	<b>8910.92</b>

For, NATRAJ PROTEINS LIMITED



Date: 03.11.2023

Place: Itarsi

**KAILASH CHAND SHARMA**  
Chairman & Managing Director  
DIN: 00012900

**Standalone Cash Flow Statement for the Year ended 30<sup>th</sup> Sept., 2023**

(Rupees in Lakhs)

	For the Half Year ended 30.09.2023	For the Year ended 31.03.2023
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
<b>NET PROFIT BEFORE TAXATION AND EXTRAORDINARY ITEM</b>	(1174.71)	101.29
<b>ADJUSTMENT FOR:</b>		
Depreciation and amortization expenses	20.89	42.71
Interest Paid	147.18	175.97
Interest Income	(8.17)	(9.56)
Others	2.86	(10.69)
<b>Operating Profit before Working Capital Changes</b>	<b>(1011.95)</b>	<b>299.72</b>
<b>ADJUSTMENTS FOR</b>		
Trade receivables	381.83	510.46
Inventories	2905.40	(1618.31)
loans, advances and other assets	168.04	(285.97)
Other Current Assets	15.25	88.10
Non-Current liabilities		(6.61)
Current liabilities	(2095.98)	1311.80
<b>CASH GENERATED FROM OPERATIONS</b>		
Income tax paid		(19.50)
Indirect tax paid		-
Total Adjustments	1374.53	(20.03)
<b>NET CASH FROM OPERATING ACTIVITIES</b>	<b>362.59</b>	<b>279.69</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of property, plant and equipment, Intangibles etc,	(4.64)	(214.27)
Non-current Assets, Long-term Loans and Advances	59.36	(83.59)
Purchase of Mutual Funds	-	(10.00)
Redemption of Mutual Funds	-	15.52
Interest received	8.17	9.56
<b>NET CASH USED IN/ FROM INVESTING ACTIVITIES</b>	<b>62.89</b>	<b>(282.77)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds from Long-term borrowings	8.84	(63.57)
Proceeds from Short-term borrowings/Banks		0.00
Interest paid	(147.18)	(175.97)
<b>NET CASH USED IN/ FROM FINANCING ACTIVITIES</b>	<b>(138.34)</b>	<b>(239.54)</b>
<b>NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS</b>	<b>287.14</b>	<b>(242.62)</b>
<b>OPENING CASH AND CASH EQUIVALENTS</b>	239.58	482.20
<b>CLOSING CASH AND CASH EQUIVALENTS</b>	526.72	239.58

For, NATRAJ PROTEINS LIMITED



**KAILASH CHAND SHARMA**  
Chairman & Managing Director  
DIN: 00012900

Date: 3.11.2023  
Place: Itarsi





**Limited Review Report on Unaudited Standalone Financial Results of Natraj Proteins Limited  
for the quarter and half year ended 30<sup>th</sup> September, 2023 pursuant to Regulation 33 of the SEBI  
(LODR) Regulations, 2015**

To,  
The Board of Directors of  
**NATRAJ PROTEINS LIMITED**  
Itarsi (M.P.) 461111

We have reviewed the accompanying statement of unaudited standalone financial results of **NATRAJ PROTEINS LIMITED** (the Company) for the quarter and half year ended 30<sup>th</sup> September, 2023 (the statement).

The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s Bhutoria Ganesan & Co.

Chartered Accountants

FRN: 004465C

  
CA R. Gokulkrishnan  
(Partner)

M. No. 402792

UDIN: 23402792BGYXSE4041

Place: Bhopal

Date: 03/11/2023

